The integrated, multidimensional approach in our study lays the foundation for understanding the role of the FCGR3B gene positive subtype of MoAM in COVID-19 severity, which may pave the way for novel immune-targeted therapies. This evidence concerns the gene FCGR3B and COVID-19.